Nicotinamide Riboside (NR)

What Is Nicotinamide Riboside?

Nicotinamide Riboside (NR) is a naturally occurring form of vitamin B3 found in trace amounts in milk and other foods. Discovered as an NAD+ precursor by Dr. Charles Brenner in 2004, NR has become the most clinically studied NAD+ boosting supplement — with more peer-reviewed human pharmacokinetic and safety data than NMN or any other precursor.

NR is the active ingredient in Niagen (ChromaDex), the first commercially available NR product, which holds GRAS (Generally Recognized as Safe) status from the FDA.

The NR Pharmacokinetic Advantage

Trammell et al. (Nature Communications, 2016) conducted the first formal pharmacokinetic study of NR in humans, demonstrating:

• Dose-dependent NAD+ increase at 100, 300, and 1000mg single doses
• 2.7-fold increase in blood NAD+ after a single 1000mg dose
• 45-fold increase in NAAD (an unexpected and sensitive biomarker)
• Superior pharmacokinetics vs nicotinic acid and nicotinamide

NR is phosphorylated by NRK1/NRK2 enzymes — a different pathway than nicotinamide (which uses NAMPT, the rate-limiting enzyme for NAD+ synthesis). This NRK pathway allows NR to bypass the NAMPT bottleneck.

Human Clinical Evidence

The clinical evidence base for NR is uniquely robust:

• Martens et al. (Nature Communications, 2018) — 12-week crossover RCT in 30 healthy middle-aged and older adults. NR 500mg twice daily safely doubled blood NAD+ and showed signal for reduced systolic blood pressure and arterial stiffness.
• NCT03821623 — Ongoing larger RCT specifically targeting blood pressure reduction in 94 midlife/older adults with elevated systolic BP.
• Long-COVID trial (2025) — Double-blind RCT of 2000mg/day NR demonstrated cognitive symptom improvement.
• Parkinson's Phase I — NR enhanced NAD+ metabolome and upregulated mitochondrial pathways in blood and muscle.
• Gulf War Illness trial (NCT05243290) — Active multi-site trial of 300mg NR for mitochondrial bioenergetics restoration.

Cardiovascular Focus: The Strongest NR Indication

The most consistent clinical signal for NR is cardiovascular benefit. Mechanistically:

• Reduces oxidative stress in vascular smooth muscle
• Improves endothelial nitric oxide bioavailability
• Reduces arterial stiffness (a key mortality predictor in older adults)
• Modest blood pressure reduction in elevated-BP populations

This represents one of the strongest evidence bases for any NAD+ precursor in any indication.

NR vs NMN

The NR vs NMN debate is one of the most discussed questions in longevity supplementation. Key differences:

• Clinical evidence: NR has substantially more published human RCTs
• Cost: NR is generally less expensive per equivalent dose
• Pharmacokinetics: Both elevate NAD+ effectively
• Pathway: NR uses NRK1/2; NMN may require dephosphorylation to NR before cellular uptake (debated)
• Stability: Both stable when properly formulated

For cardiovascular and general longevity applications, NR has the strongest evidence. Some practitioners prefer NMN for muscle and metabolic applications based on Yoshino et al.'s postmenopausal women trial, though this distinction is increasingly seen as marginal.

Bioavailability and Forms

Niagen (ChromaDex) is the patented form used in most published clinical trials. Other NR products of varying quality have entered the market — for clinical-grade dosing, Niagen-licensed products provide the most quality assurance.

NR is acid-stable (unlike NMN which has stability concerns), can be taken with or without food, and has a clean side effect profile at standard doses.

Stacking Recommendations

NR stacks particularly well with:

• TMG (Trimethylglycine) — methyl donor that prevents potential methyl-group depletion from chronic NAD+ precursor supplementation
• Resveratrol — sirtuin activator that synergises with NAD+ availability
• Astaxanthin — protects mitochondria that NR provides energy substrate for

Related Research

• NMN vs NR: Which NAD+ Precursor Actually Works in 2026?
• Cardiovascular Longevity Protocol: CoQ10 + Omega-3 + Astaxanthin Stack